Table 2.

Clinical characteristics and LILAC participation status of WHI women with LILAC-designated cancers reported as of September 2015, by cancer site

TotalBreastColorectal
AllaEligiblebConsentedcAllaEligiblebConsentedcAllaEligiblebConsentedc
Nn (%)n (%)% of AllNn (%)n (%)% of AllNn (%)n (%)% of All
Total20,7849,934 (48)7,760 (78)37%9,3055,251 (56)4,211 (80)45%2,4991,039 (42)796 (77)32%
Year of diagnosis
 <20015,7131,896 (33)1,451 (77)25%2,8021,161 (41)905 (78)32%758203 (27)148 (73)20%
 2001-20056,5982,623 (40)2,019 (77)31%3,0411,490 (49)1,183 (79)39%801277 (35)208 (75)26%
 2006-20105,1802,898 (56)2,312 (80)45%2,1411,492 (70)1,228 (82)57%580294 (51)229 (78)39%
 2011-20153,2932,517 (76)1,978 (79)60%1,3211,108 (84)895 (81)68%360265 (74)211 (80)59%
Age at diagnosis
 50-591,182591 (50)496 (84)42%681385 (57)329 (85)48%9838 (39)26 (68)27%
 60-696,3913,257 (51)2,597 (80)41%3,1461,864 (59)1,526 (82)49%658278 (42)217 (78)33%
 70-799,4524,475 (47)3,496 (78)37%4,1012,272 (55)1,807 (80)44%1,135489 (43)384 (79)34%
 80-893,5581,513 (43)1,109 (73)31%1,318694 (53)524 (76)40%554212 (38)154 (73)28%
 90+20198 (49)62 (63)31%5936 (61)25 (69)42%5422 (41)15 (68)28%
Stage at diagnosis
 In situ855578 (68)344 (60)40%
 Local11,2356,461 (58)5,169 (80)46%6,9514,075 (59)3,285 (81)47%1,107591 (53)458 (77)41%
 Regional4,3481,932 (44)1,522 (79)35%2,1181,113 (53)883 (79)42%1,021411 (40)308 (75)30%
 Distant2,929557 (19)431 (77)15%13231 (23)21 (68)16%31831 (10)26 (84)8%
 Unknown727153 (21)108 (71)15%10432 (31)22 (69)21%536 (11)4 (67)8%
Morphology grade
 Well differentiated3,1731,906 (60)1,496 (78)47%2,3971,512 (63)1,210 (80)50%18594 (51)66 (70)36%
 Moderately differentiated6,5383,423 (52)2,739 (80)42%3,8532,232 (58)1,799 (81)47%1,514654 (43)512 (78)34%
 Anaplastic/poorly differentiated4,5681,890 (41)1,527 (81)33%2,2531,157 (51)926 (80)41%566203 (36)160 (79)28%
 Unknown2,666693 (26)527 (76)20%802350 (44)276 (79)34%23488 (38)58 (66)25%
Tumor size, cm
 ≤0.51,7241,070 (62)836 (78)48%1,115668 (60)538 (81)48%7844 (56)26 (59)33%
 >0.5-12,8101,669 (59)1,350 (81)48%2,3761,420 (60)1,146 (81)48%6537 (57)28 (76)43%
 >1-24,5022,504 (56)2,035 (81)45%3,5102,024 (58)1,653 (82)47%18394 (51)76 (81)42%
 >2-54,4461,889 (42)1,489 (79)33%1,706873 (51)683 (78)40%1,093451 (41)353 (78)32%
 >51,467541 (37)433 (80)30%247116 (47)89 (77)36%542211 (39)169 (80)31%
 Unknown3,8311,426 (37)980 (69)26%351150 (43)102 (68)29%538202 (38)144 (71)27%
LungEndometrialLeukemia
AlldEligibleeConsentedfAllaEligiblebConsentedcAllaEligiblebConsentedc
Nn (%)n (%)% of AllNn (%)n (%)% of AllNn (%)n (%)% of All
Total2,628534 (20)406 (76)15%1,509839 (56)663 (79)44%690253 (37)186 (74)27%
Year of diagnosis
 <200161440 (7)32 (80)5%448202 (45)149 (74)33%14819 (13)13 (68)9%
 2001–200579277 (10)57 (74)7%484226 (47)178 (79)37%20062 (31)46 (74)23%
 2006–2010773182 (24)151 (83)20%365235 (64)188 (80)52%21690 (42)64 (71)30%
 2011–2015449235 (52)166 (71)37%212176 (83)148 (84)70%12682 (65)63 (77)50%
Age at diagnosis
 50–59737 (10)6 (86)8%9460 (64)51 (85)54%164 (25)3 (75)19%
 60–69643115 (18)90 (78)14%545317 (58)253 (80)46%19280 (42)63 (79)33%
 70–791,317277 (21)213 (77)16%661363 (55)288 (79)44%319114 (36)82 (72)26%
 80–89564130 (23)96 (74)17%20194 (47)68 (72)34%15754 (34)37 (69)24%
 90+315 (16)1 (20)3%85 (63)3 (60)38%61 (17)1 (100)17%
Stage at diagnosis
In situ
 Local688308 (45)249 (81)36%1,204720 (60)570 (79)47%
 Regional610142 (23)108 (76)18%21197 (46)80 (82)38%
 Distant1,01864 (6)37 (58)4%7815 (19)10 (67)13%
 Unknown31220 (6)12 (60)4%167 (44)3 (43)19%
Morphology grade
 Well differentiated255110 (43)81 (74)32%310179 (58)130 (73)42%
 Moderately differentiated465152 (33)122 (80)26%593350 (59)281 (80)47%
 Anaplastic/poorly differentiated657109 (17)88 (81)13%533272 (51)220 (81)41%
 Unknown1,251163 (13)115 (71)9%7338 (52)32 (84)44%
Tumor size, cm
 ≤0.5184 (22)4 (100)22%5534 (62)24 (71)44%
 >0.5–19342 (45)38 (90)41%5033 (66)26 (79)52%
 >1–2431169 (39)124 (73)29%176116 (66)94 (81)53%
 >2–51,013225 (22)172 (76)17%457266 (58)218 (82)48%
 >533862 (18)46 (74)14%12157 (47)44 (77)36%
 Unknown73532 (4)22 (69)3%650333 (51)257 (77)40%
Non-Hodgkin lymphomaMelanomagEOCh
AlliEligiblejConsentedkAllcEligibledConsentedeAllcEligibledConsentede
Nn (%)n (%)% of AllNn (%)n (%)% of AllNn (%)n (%)% of All
Total1,314582 (44)451 (77)34%1,8351,187 (65)834 (70)45%1,004249 (25)213 (86)21%
Year of diagnosis
 <200129169 (24)52 (75)18%372169 (45)123 (73)33%28033 (12)29 (88)10%
 2001–2005436149 (34)110 (74)25%530303 (57)202 (67)38%31439 (12)35 (90)11%
 2006–2010369202 (55)162 (80)44%480320 (67)218 (68)45%25683 (32)72 (87)28%
 2011–2015218162 (74)127 (78)58%453395 (87)291 (74)64%15494 (61)77 (82)50%
Age at diagnosis
 50–595615 (27)12 (80)21%11568 (59)58 (85)50%4914 (29)11 (79)22%
 60–69331160 (48)127 (79)38%554377 (68)262 (69)47%32266 (20)59 (89)18%
 70–79635303 (48)235 (78)37%826533 (65)380 (71)46%458124 (27)107 (86)23%
 80–8927493 (34)70 (75)26%321192 (60)125 (65)39%16944 (26)35 (80)21%
 90+1811 (61)7 (64)39%1917 (89)9 (53)47%61 (17)1 (100)17%
Stage at diagnosis
In situ855579 (68)344 (59)40%
 Local313139 (44)103 (74)33%879573 (65)457 (80)52%9355 (59)47 (85)51%
 Regional17985 (47)64 (75)36%6024 (40)23 (96)38%14960 (40)56 (93)38%
 Distant624282 (45)228 (81)37%191 (5)0 (0)0%740133 (18)109 (82)15%
 Unknown19876 (38)56 (74)28%2210 (45)10 (100)45%221 (5)1 (100)5%
Morphology grade
 Well differentiated2611 (42)9 (82)35%
 Moderately differentiated11335 (31)25 (71)22%
 Anaplastic/poorly differentiated559149 (27)133 (89)24%
 Unknown30654 (18)46 (85)15%
Tumor size, cm
 ≤0.5445313 (70)239 (76)54%137 (54)5 (71)38%
 >0.5–1209135 (65)110 (81)53%172 (12)2 (100)12%
 >1–216192 (57)80 (87)50%419 (22)8 (89)20%
 >2–58136 (44)31 (86)38%9638 (40)32 (84)33%
 >5187 (39)6 (86)33%20188 (44)79 (90)39%
 Unknown921604 (66)368 (61)40%636105 (17)87 (83)14%
  • aParticipants with reported and centrally confirmed eligible cancers in WHI as of September 30, 2015.

  • bEligible for LILAC invitation mailing (in active follow-up at LILAC initiation with prior confirmed cancer or subsequently diagnosed with a qualifying cancer).

  • cProvided written consent for LILAC data collection activities.

  • dParticipants with reported and centrally confirmed eligible cancers in WHI as of September 30, 2015.

  • eEligible for LILAC invitation mailing (in active follow-up at LILAC initiation with prior confirmed cancer or subsequently diagnosed with a qualifying cancer).

  • fProvided written consent for LILAC data collection activities.

  • gMelanoma includes both in situ and invasive cancers.

  • hOvarian, fallopian tube and primary peritoneal cancer.

  • iParticipants with reported and centrally confirmed eligible cancers in WHI as of September 30, 2015.

  • jEligible for LILAC invitation mailing (in active follow-up at LILAC initiation with prior confirmed cancer or subsequently diagnosed with a qualifying cancer).

  • kProvided written consent for LILAC data collection activities.